Modular Design of Mesoporous Silica Nanoparticles Enables Bioimaging, Dual Chemotherapy, and Combinatorial Gene Silencing in Triple-Negative Breast Cancer
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Triple-negative breast cancer (TNBC) accounts for 10-15% of all breast cancers and remains the most aggressive subtype due to its resistance to standard chemotherapy. A key factor behind its resistance is the activation of antiapoptotic pathways, which help tumor cells evade drug-induced death. We present a modular platform for combinatorial therapy, simultaneously delivering different clinically approved chemotherapeutics and RNAi agents targeting multiple survival pathways in vitro. To ensure that therapeutic activation occurs only after cellular uptake, mesoporous silica nanoparticles were functionalized with cisplatin and gemcitabine via reduction-sensitive linkers, while surface modification with polyethylenimine enabled pH-responsive release of programmable RNA nanoparticles that, upon intracellular dicing, produce DS RNAs targeting the expression of Survivin and BCL-2. This optimized formulation achieved strong gene silencing, minimized immune activation, and enhanced cytotoxicity in TNBC cells compared to either treatment alone. The results highlight the potential of this combinatorial strategy to overcome chemoresistance by delivering multiple therapeutics that simultaneously target distinct survival pathways in cancer cells and can be readily modified and adapted to new targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This apparent paradox is mechanistically plausible: highly glycolytic, rapidly proliferating cells in in vitro monolayer systems exhibit heightened sensitivity to cell-cycle-targeting drugs (13, 14).”
From Bioinformatics-based identification of glycolysis-related signatures associated with drug resistance and prognosis in lung adenocarcinoma (2026) · cites this paper as [13]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers☆
SLOWING, I., VIVEROESCOTO, J., WU, C., & LIN, V (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.03.012 · Cited by 2,653
Self-citationBreast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891
DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
Pommier, Y., Leo, E., Zhang, H., & Marchand, C. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.04.012 · Cited by 1,829
Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy
Li, X., Lewis, M. T., Huang, J., Gutierrez, C., Osborne, C. K., Wu, M.-F., Hilsenbeck, S. G., Pavlick, A., Zhang, X., Chamness, G. C., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn123 · Cited by 1,794
Doxorubicin pathways: pharmacodynamics and adverse effects
Thorn, C. F., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, T. E., & Altman, R. B. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833ffb56 · Cited by 1,648
Direct Cellular Responses to Platinum-Induced DNA Damage
Jung, Y., & Lippard, S. J. (2007) · Chemical Reviews · doi:10.1021/cr068207j · Cited by 1,391
Mesoporous Silica Nanoparticles for Intracellular Controlled Drug Delivery
Vivero‐Escoto, J. L., Slowing, I. I., Trewyn, B. G., & Lin, V. S. ‐. (2010) · Small · doi:10.1002/smll.200901789 · Cited by 998
Self-citationXia, T., Kovochich, M., Liong, M., Meng, H., Kabehie, S., George, S., Zink, J. I., & Nel, A. E. (2009) · ACS Nano · doi:10.1021/nn900918w · Cited by 933
Tewey, K. M., Chen, G. L., Nelson, E. M., & Liu, L. F. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)47282-6 · Cited by 887
Nedeljković, M., & Damjanović, A. (2019) · Cells · doi:10.3390/cells8090957 · Cited by 870
Predicting drug sensitivity and resistance
Szakács, G., Annereau, J.-P., Lababidi, S., Shankavaram, U., Arciello, A., Bussey, K. J., Reinhold, W., Guo, Y., Kruh, G. D., Reimers, M., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.026 · Cited by 531
Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?
Vallet-Regí, M., Schüth, F., Lozano, D., Colilla, M., & Manzano, M. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00659b · Cited by 507
Mesoporous silica nanoparticles: structural design and applications
Slowing, I. I., Vivero-Escoto, J. L., Trewyn, B. G., & Lin, V. S.-Y. (2010) · Journal of Materials Chemistry · doi:10.1039/c0jm00554a · Cited by 426
Self-citationSurvivin expression and targeting in breast cancer
Jha, K., Shukla, M., & Pandey, M. (2012) · Surgical Oncology · doi:10.1016/j.suronc.2011.01.001 · Cited by 162
Gao, Y., Gao, D., Shen, J., & Wang, Q. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.598722 · Cited by 147
Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance
Hill, D. P., Harper, A., Malcolm, J., McAndrews-Hill, M., Mockus, S. M., Patterson, S. E., Reynolds, T., Baker, E. J., Bult, C. J., Chesler, E. J., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6278-9 · Cited by 137
Structure and Composition Define Immunorecognition of Nucleic Acid Nanoparticles
Hong, E., Halman, J. R., Shah, A. B., Khisamutdinov, E. F., Dobrovolskaia, M. A., & Afonin, K. A. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b01283 · Cited by 136
Self-citationNanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy
Xiao, B., Ma, L., & Merlin, D. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1205583 · Cited by 135
Tumor-specific gene expression using the survivin promoter is further increased by hypoxia
Li, Y., Cao, Z., Li, F., Post, D. E., Meir, E. G. V., Zhong, H., & Wood, W. C. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302280 · Cited by 115
Subbaiah, M. A. M., Rautio, J., & Meanwell, N. A. (2024) · Chemical Society Reviews · doi:10.1039/d2cs00957a · Cited by 115
Belyanskaya, L. L., Hopkins-Donaldson, S., Kurtz, S., Simões‐Wüst, A. P., Yousefi, S., Simon, H., Stahel, R. A., & Zangemeister‐Wittke, U. (2005) · International Journal of Cancer · doi:10.1002/ijc.21242 · Cited by 113
BCL2 as a Subtype-Specific Prognostic Marker for Breast Cancer
Eom, Y. H., Kim, H., Lee, A., Song, B. J., & Chae, B. J. (2016) · Journal of Breast Cancer · doi:10.4048/jbc.2016.19.3.252 · Cited by 109
Abdel-Fatah, T. M. A., Perry, C., Dickinson, P. D., Ball, G., Moseley, P. M., Madhusudan, S., Ellis, I. O., & Chan, S. Y. T. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt277 · Cited by 94
Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin
Inao, T., Iida, Y., Moritani, T., Okimoto, T., Tanino, R., Kotani, H., & Harada, M. (2018) · Oncotarget · doi:10.18632/oncotarget.25370 · Cited by 79
Tarannum, M., & Vivero-Escoto, J. L. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114357 · Cited by 76
Self-citationRNA Fibers as Optimized Nanoscaffolds for siRNA Coordination and Reduced Immunological Recognition
Rackley, L. E., Stewart, J. M., Salotti, J., Krokhotin, A., Shah, A. B., Halman, J. R., Juneja, R., Smollett, J., Lee, L., Roark, K., et al. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201805959 · Cited by 74
Self-citationJohnson, M. B., Chandler, M. R., & Afonin, K. A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.011 · Cited by 69
Self-citationRecent Applications of Mesoporous Silica Nanoparticles in Gene Therapy
Huq, T. B., Jeeja, P. A. K., Dam, S. K., Das, S. S., & Vivero-Escoto, J. L. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202404781 · Cited by 63
Self-citationChandler, M. R., Jain, S., Halman, J. R., Hong, E., Dobrovolskaia, M. A., Zakharov, A. V., & Afonin, K. A. (2022) · Small · doi:10.1002/smll.202204941 · Cited by 62
Self-citationKim, T., Afonin, K. A., Viard, M., Koyfman, A. Y., Sparks, S., Heldman, E., Grinberg, S., Linder, C., Blumenthal, R. P., & Shapiro, B. A. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.5 · Cited by 61
Self-citationHalman, J. R., Kim, K.-T., Gwak, S., Pace, R., Johnson, M. B., Chandler, M. R., Rackley, L. E., Viard, M., Marriott, I., Lee, J. S., et al. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2019.102094 · Cited by 60
Self-citationGuo, Q., Chen, Y., Zhang, B., Kang, M., Xie, Q., & Wu, Y. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.02.021 · Cited by 56
Tawfik, K. O., Kimler, B. F., Davis, M., Fan, F., & Tawfik, O. W. (2011) · Human Pathology · doi:10.1016/j.humpath.2011.04.011 · Cited by 56
Dobrovolskaia, M. A., & Afonin, K. A. (2020) · Nature Protocols · doi:10.1038/s41596-020-0393-6 · Cited by 55
Self-citationJuneja, R., Vadarevu, H., Halman, J. R., Tarannum, M., Rackley, L. E., Dobbs, J., Marquez, J., Chandler, M. R., Afonin, K. A., & Vivero-Escoto, J. L. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c07106 · Cited by 54
Self-citationFaversani, A., Vaira, V., Moro, G. P., Tosi, D., Lopergolo, A., Schultz, D. C., Rivadeneira, D., Altieri, D. C., & Bosari, S. (2014) · Breast Cancer Research · doi:10.1186/bcr3666 · Cited by 51
Paramanantham, A., Jung, E., Kim, H. J., Jeong, B. K., Jung, J., Kim, G. S., Hong, S., & Lee, W. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212438 · Cited by 51
Smart-Responsive Nucleic Acid Nanoparticles (NANPs) with the Potential to Modulate Immune Behavior
Chandler, M. R., & Afonin, K. A. (2019) · Nanomaterials · doi:10.3390/nano9040611 · Cited by 49
Self-citationSurvivin mRNA expression in patients with breast cancer.
Nasu, S., Yagihashi, A., Izawa, A., et al. (2002) · PubMed · Cited by 49
Juneja, R., Lyles, Z., Vadarevu, H., Afonin, K. A., & Vivero-Escoto, J. L. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b00704 · Cited by 46
Self-citationPaul, A., Eun, C.-J., & Song, J. M. (2014) · Polymer · doi:10.1016/j.polymer.2014.08.043 · Cited by 46
Dual Approaches in Oncology: The Promise of siRNA and Chemotherapy Combinations in Cancer Therapies
Sousa, C., & Videira, M. (2025) · Onco · doi:10.3390/onco5010002 · Cited by 44
Tarannum, M., Hossain, M. A., Holmes, B. M., Yan, S., Mukherjee, P., & Vivero-Escoto, J. L. (2021) · Small · doi:10.1002/smll.202104449 · Cited by 44
Self-citationAdvances in Nanomaterials Used in Co-Delivery of siRNA and Small Molecule Drugs for Cancer Treatment
Chung, S. L., Yee, M. S.-L., Hii, L., Lim, W., Ho, M. Y., Khiew, P. S., & Leong, C. (2021) · Nanomaterials · doi:10.3390/nano11102467 · Cited by 40
Parvani, J. G., & Jackson, M. W. (2017) · Endocrine Related Cancer · doi:10.1530/erc-16-0482 · Cited by 40
Characterization of Cationic Bolaamphiphile Vesicles for siRNA Delivery into Tumors and Brain
Kim, T., Viard, M., Afonin, K. A., Gupta, K., Popov, M., Salotti, J., Johnson, P. F., Linder, C., Heldman, E., & Shapiro, B. A. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.02.011 · Cited by 37
Self-citationLiu, W., Zhu, F., Jiang, Y., Sun, D., Yang, B., & Yan, H. (2012) · Oncology Reports · doi:10.3892/or.2012.2196 · Cited by 34
Smoots, S. G., Schreiber, A., Jackson, M. M., Bagby, S. M., Dominguez, A. T. A., Dus, E. D., Binns, C. A., MacBeth, M. L., Whitty, P. A., Diamond, J. R., et al. (2024) · Breast Cancer Research · doi:10.1186/s13058-024-01799-5 · Cited by 32
Nanoparticle combination for precise stroma modulation and improved delivery for pancreatic cancer
Tarannum, M., Holtzman, K., Dréau, D., Mukherjee, P., & Vivero-Escoto, J. L. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.019 · Cited by 29
Self-citationNew Strategies in Melanoma Therapy: Can Nanoparticles Overcome Chemoresistance?
Badea, I. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0145 · Cited by 29
Prodrugs in Oncology: Bioactivation and Impact on Therapeutic Efficacy and Toxicity
Kurian, R., & Wang, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26030988 · Cited by 28
Anhydrous Nucleic Acid Nanoparticles for Storage and Handling at Broad Range of Temperatures
Tran, A., Chandler, M. R., Halman, J. R., Beasock, D., Fessler, A. B., McKeough, R. Q., Lam, P. A., Furr, D. P., Wang, J., Cedrone, E., et al. (2022) · Small · doi:10.1002/smll.202104814 · Cited by 27
Self-citationSurvivin expression induced by doxorubicin in cholangiocarcinoma
Chang, Q., Liu, Z.-R., Wang, D.-Y., Kumar, M., Chen, Y.-B., & Qin, R. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i3.415 · Cited by 21
Ke, W., Chandler, M. R., Cedrone, E., Saito, R. D. F., Rangel, M. C., Junqueira, M. D. S., Wang, J., Shi, D., Trưởng, N. V., Richardson, M., et al. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c02019 · Cited by 21
Self-citationVivero-Escoto, J. L., Vadarevu, H., Juneja, R., Schrum, L. W., & Benbow, J. H. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb01845j · Cited by 21
Self-citationKostadima, L., Pentheroudakis, G. E., Fountzilas, G., Dimopoulos, M. A., Pectasides, D. G., Gogas, H. J., Christodoulou, C., Samantas, E., Bafaloukos, D. I., Arapantoni, P., et al. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9240-x · Cited by 19
Rebolledo, L. P., Ke, W., Cedrone, E., Wang, J., Majithia, K. J., Johnson, M. B., Dokholyan, N. V., Dobrovolskaia, M. A., & Afonin, K. A. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c17779 · Cited by 17
Self-citationAvila, Y. I., Rebolledo, L. P., Santos, N. L., Rawlins, B., Radwan, Y., Andrade-Muñoz, M., Skelly, E., Chandler, M. R., Andrade, L. N. D. S., Kim, T. J., et al. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5c00336 · Cited by 15
Self-citationRelevance of c-erbB2, PLU-1 and survivin mRNA expression to diagnostic assessment of breast cancer.
Izawa, A., Kobayashi, D., Nasu, S., et al. (2003) · PubMed · Cited by 14
Avila, Y. I., Ha, A. T., Chandler, M. R., Santos, N. L., Kim, T., Newton, H. S., Dobrovolskaia, M. A., & Afonin, K. A. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202508122 · Cited by 12
Self-citationSurvivin expression as a prognostic marker for breast cancer
Quidute, P., Quidute, R. S., Perez, M. M., Pereira, E. C., da Veiga, G. L., Alves, B. D. C. A., & Fonseca, F. L. A. (2023) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20230167 · Cited by 9
New Approach Methodologies in Drug Development
von Keutz, E. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104475 · Cited by 5
The prognostic role of survivin expression in breast cancer: A systematic review and meta-analysis
Kucukzeybek, B. B., Küçükzeybek, Y., Başbınar, Y., Ellıdokuz, H., Tekindal, M. A., Dinçkal, Ç., & Tarhan, M. O. (2024) · Medicine · doi:10.1097/md.0000000000040013 · Cited by 5
Research works printed but not linked: 3
- 2022, Treatment of Triple-Negative Breast Cancer
- Nasu S., 2002, Anticancer Res., 22, 1839
- Izawa A., 2002, Anticancer Res., 22, 2965
Cited by
Zheng, Q., Liu, Y., Li, T., Zhang, X., Geng, Y., Chen, Z., Zhou, J., Fan, W., Wang, Y., Zhang, L., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1871582
“This apparent paradox is mechanistically plausible: highly glycolytic, rapidly proliferating cells in in vitro monolayer systems exhibit heightened sensitivity to cell-cycle-targeting drugs (13, 14).”
Radwan, Y., Rebolledo, L. P., Avila, Y. I., Skelly, E., Rackley, L. E., Hernandez, J. N., Saito, R. D. F., Pandey, L. K., Chhabra, H., Lushnikov, A. J., et al. (2026) · Small · doi:10.1002/smll.202600078
Self-citationLiu, L., Yan, Y., Zhang, J., Guan, Z., Liu, M., Wang, X., Duan, X., & Su, C. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6c05220
Progress of siRNA Nanomedicines in Modulating the Microenvironment of Triple-Negative Breast Cancer
Long, Y., Yin, H., Li, J., & Zhang, W. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s629428
Radwan, Y., Rebolledo, L. P., Skelly, E., Grabarnik, E., Jain, S., Halman, M., Chammas, R. J., Zakharov, A. V., Dobrovolskaia, M. A., & Afonin, K. A. (2026) · Chemical Society Reviews · doi:10.1039/d6cs01323f
Self-citation
Metadata
- Authors
- Rebolledo, L. P., Anil Kumar Jeeja, P., Danai, L., Binte Huq, T., Afonin, K. A., & Vivero-Escoto, J. L.
- Affiliations
- University of North Carolina at Charlotte (US)
- Department of Chemistry
- Corresponding author
- Afonin, Kirill A.
- Vivero-Escoto, Juan L.
- Venue
- ACS Applied Materials & Interfaces
- Publisher
- American Chemical Society (ACS)
- Published
- 2025-12-15
- Volume
- 17
- Issue
- 51
- Pages
- 68925-68938
- ISSN
- 1944-8244 (ISSN-L)
- 1944-8252
- PMC
- PMC12754758
- OpenAlex
- W4417315040
- Cited by
- 4
- References
- 61
- Citations by year
- 2026: 4
- FWCI
- 0.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- ACS Applied Materials & Interfaces (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Funders
- National Cancer Institute (R01CA263897, R15CA274239)
- National Institute of General Medical Sciences (R35GM139587)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Keywords
- triple-negative breast cancer, mesoporous silica nanoparticles, chemoresistance, RNA interference, gene silencing, cisplatin, gemcitabine, pH-responsive drug release, polyethyleneimine, survivin, Bcl-2, anti-apoptotic pathways, bioimaging, combination therapy
- MeSH terms
- Survivin, Gemcitabine, Antineoplastic Agents, Cisplatin, Deoxycytidine, Female, Humans, Silicon Dioxide, Porosity, Proto-Oncogene Proteins c-bcl-2, Gene Silencing, Cell Line, Tumor, Nanoparticles, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.